Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07601750

Local Anesthetic Clinical Trial

To compare several local anesthetics when used during dermatological surgery.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Mohs Micrographic Surgery Anesthesia, Local

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Baylor University Medical Center

Dallas, Texas, 75246, United States

About this study

This study is a randomized, controlled trial comparing the effectiveness of several local anesthetics, including lidocaine, mepivacaine, bupivacaine, and chlorprocaine when used for Mohs Microscopic Surgery (MMS) to see which is the most effective.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adults 18-89 years old
  • individuals with a cutaneous tumor treated by MMS

Exclusion criteria

  • individuals younger than 18 and older than 89
  • pregnant individuals

Treatment and study plan

Lidocaine

Drug

Standard of Care drug

Bupivacaine Hydrochloride

Drug

Study Drug

Mepivacaine Hydrochloride

Drug

Study Drug

Other names: Carbocaine

Chlorprocaine

Drug

Study Drug

Primary outcomes

  1. Determine if pain increases with local injections at each stage of surgery.

    Time frame: 5 mins, 15 mins, 20 mins, 25 mins, 30 mins, 45 mins (reconstruction)

    Assess changes in pain levels by determining if longer acting agents such as bupivacaine or bupivacaine with epinephrine will show lower reported pain scores by patients compared to shorter acting anesthetic agents such as lidocaine with epinephrine or mepivacaine when undergoing Mohs micrographic surgery. Patients will rate their pain verbally using the visual analog scale (VAS) of 1-10, where 1 is no pain and 10 is worst pain possible.

Secondary outcomes

  1. Pain control using mepivacaine as a primary anesthetic agent

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Determine if using mepivacaine as the primary anesthetic will lower the patient verbally reported pain scores. Patients will rate their pain verbally using the visual analog scale (VAS) of 1-10, where 1 is no pain and 10 is worst pain possible.

  2. Pain control using bupivacaine with epinephrine as a primary anesthetic agent

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Determine change in patients verbally reported pain scale when using bupivacaine with epinephrine as the primary anesthetic. Patients will rate their pain verbally using the visual analog scale (VAS) of 1-10, where 1 is no pain and 10 is worst pain possible.

  3. Pain control using bupivacaine as a primary anesthetic agent

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Determine change in patients verbally reported pain scale when using bupivacaine as the primary anesthetic. Patients will rate their pain verbally using the visual analog scale (VAS) of 1-10, where 1 is no pain and 10 is worst pain possible.

  4. Ideal anesthetic agents for varying sizes of tumors

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Determine which anesthetic works best for different size tumors. This will be measured using pain scores throughout the procedure prior to taking the stage as the patient will be numb after the stage is taken. The visual analog scale (VAS) of 1-10 will be used, where 1 means no pain and 10 is worst pain possible.

  5. Ideal anesthetic agents for varying anatomic location of tumors

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Determine which anesthetic works best for tumors in different locations of the body. This will be measured using pain scores throughout the procedure prior to taking the stage as the patient will be numb after the stage is taken. The visual analog scale (VAS) of 1-10 will be used, where 1 means no pain and 10 is worst pain possible.

  6. Overall tolerability of MMS

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Assess patients ability to tolerate the surgery with different anesthetics. This will be measured using pain scores throughout the procedure prior to taking the stage as the patient will be numb after the stage is taken. The visual analog scale (VAS) of 1-10 will be used, where 1 means no pain and 10 is worst pain possible.

  7. General length of time required for various steps of MMS

    Time frame: 5 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes (reconstruction)

    Assess the length of time it took to move from one stage to the next.

Sponsors and collaborators

Lead sponsor

Baylor Research Institute

Other

Registry information

Official study title

Incidence of Pain During Reanesthetization in Mohs Micrographic Surgery Using Lidocaine, Bupivacaine, Chlorprocaine or Mepivacaine: A Multicenter, Randomized Controlled Trial

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
May 22, 2026
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.